Education in the Era of Emerging Hemophilia Therapy (Round 2) Grant

The Education in the Era of Emerging Hemophilia Therapy (Round 2) grant, funded by Pfizer and the National Bleeding Disorders Foundation, aims to support independent medical education initiatives. This funding opportunity focuses on providing equitable education for hemophilia patients and training for healthcare professionals. The goal is to enhance understanding of emerging therapies and improve treatment choices, ultimately leading to better patient outcomes in managing hemophilia.

Pfizer
Pfizer External Research & Grants (ER&G) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
National Bleeding Disorders Foundation
The National Bleeding Disorder Foundation (NBDF) is dedicated to finding cures for inheritable blood and bleeding disorders and to addressing and preventing the complications of these disorders through research, education, and advocacy enabling people and families to thrive.
Education in the Era of Emerging Hemophilia Therapy (Round 2) Independent Medical Education Grant
Introduction
Pfizer and the National Bleeding Disorders Foundation are collaborating to offer another grant opportunity seeking proposals for independent medical education initiatives that will provide:
Equitable education for people living with hemophilia to empower them to make evidence-based treatment choices.Education for physicians and multidisciplinary teams (MDTs) to enable shared decisions making (SDM) discussions on the emerging therapeutic options for treatment of hemophilia.
Grants will be awarded in support of local (grass roots) independent medical education initiatives that will result in the measurable improvement of the medical and scientific understanding of emerging treatment options for people living with hemophilia and the MDTs that provide them care.